{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:09:29Z","timestamp":1780708169305,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ijantimicag.2016.06.016","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T22:32:40Z","timestamp":1469658760000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Pharmacokinetics and safety\/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients"],"prefix":"10.1016","volume":"48","author":[{"given":"Vycke","family":"Yunivita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiati","family":"Dian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Rizal","family":"Ganiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ela","family":"Hayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri","family":"Hanggono Achmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atu","family":"Purnama Dewi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marga","family":"Teulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Meijerhof-Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rovina","family":"Ruslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0010","author":"World Health Organization"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0015","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1474-4422(13)70168-6","article-title":"Tuberculous meningitis: more questions, still too few answers","volume":"12","author":"Thwaites","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0030","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics\u2013pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","article-title":"Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model","volume":"187","author":"de Steenwinkel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0040","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0045","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600\u2009mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0055","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","article-title":"Tuberculous meningitis: a uniform case definition for use in clinical research","volume":"10","author":"Marais","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0060","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0065","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0070","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1128\/AAC.00447-09","article-title":"Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes","volume":"54","author":"Ruslami","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0080","first-page":"500","article-title":"Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers","volume":"8","author":"van Crevel","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijantimicag.2014.12.027","article-title":"Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis","volume":"45","author":"Te Brake","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0090","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0031-6989(84)80050-8","article-title":"Pharmacokinetic study on intravenous rifampicin in man","volume":"16","author":"Acocella","year":"1984","journal-title":"Pharmacol Res Commun"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics\u2013pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0100","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"PanACEA Consortium. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0105","series-title":"High-dose rifampin, SQ109 and moxifloxacin for treating TB: the PanACEA MAMS-TB trial","author":"Boeree","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0110","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.06.016_bib0115","first-page":"2187","article-title":"High dose rifampicin for tuberculous meningitis in Vietnam: high enough?","volume":"374","author":"van Crevel","year":"2016","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916301856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916301856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T06:25:29Z","timestamp":1536560729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916301856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0924857916301856"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.06.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety\/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}